Consensus of the Spanish Society of Medical Oncology (SEOM) and Spanish Society of Pathology (SEAP) for HER2 testing in gastric carcinoma

Clinical and Translational Oncology

Volumn 13, Issue 9, 2011, Pages 636-651

  Gómez Martín, Carlos ^a   Concha, Ángel ^b   Corominas, José María ^c   García Caballero, Tomás ^d   García García, Elena ^e   Iglesias, Mar ^c   López, José Antonio ^f   Ramón Y Cajal, Santiago ^g   Rojo, Federico ^h   Palacios, José ⁱ   Vera Sempere, Francisco ^j   Aranda, Enrique ^k   Colomer, Ramon ^l   García Alfonso, Pilar ^m   Garrido, Pilar ⁿ   Rivera, Fernando ^o   López Ríos, Fernando ^e  

^a Centro Nacional de Investigaciones Oncológicas   (Spain)

^b HOSPITAL UNIVERSITARIO VIRGEN DE LAS NIEVES   (Spain)

^c HOSPITAL DEL MAR   (Spain)

^d Instituto de Salud Carlos III   (Spain)

^e UNIVERSIDAD SAN PABLO CEU   (Spain)

^f HOSPITAL UNIVERSITARIO PRÍNCIPE DE ASTURIAS   (Spain)

^g HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^h 28400 Madrid   (Spain)

ⁱ HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^j UNIVERSITY OF VALENCIA   (Spain)

^k HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

^l MD ANDERSON CANCER CENTER   (Spain)

^m HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

ⁿ HOSPITAL RAMÓN Y CAJAL   (Spain)

^o HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

more..

Author keywords

Gastric carcinoma; HER2; Immunohistochemistry; In situ hybridisation; Quality control; Standardisation

Indexed keywords

CAPECITABINE; CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FLUOROURACIL; TRASTUZUMAB; TUMOR MARKER;

ALGORITHM; ARTICLE; BREAST CARCINOMA; CANCER CELL; CANCER DIAGNOSIS; CANCER SURVIVAL; CLINICAL COMPETENCE; CONSENSUS DEVELOPMENT; DIAGNOSTIC TEST; FALSE NEGATIVE RESULT; FALSE POSITIVE RESULT; FLUORESCENCE IN SITU HYBRIDIZATION; GENE ACTIVATION; GENE AMPLIFICATION; GENE FUNCTION; GENE OVEREXPRESSION; GENETIC SCREENING; GENETIC TRANSCRIPTION; HEALTH CARE PERSONNEL; HEALTH PROGRAM; HUMAN; IMMUNOHISTOCHEMISTRY; METASTASIS; ONCOGENE NEU; OVERALL SURVIVAL; PRACTICE GUIDELINE; QUALITY CONTROL; STOMACH CARCINOMA; SURVIVAL RATE; TISSUE FIXATION; TUMOR BIOPSY; CARCINOMA; CLINICAL TRIAL (TOPIC); CONSENSUS; DIAGNOSTIC PROCEDURES; GENETICS; LEGAL ASPECT; MEDICAL SOCIETY; METHODOLOGY; MOLECULAR PATHOLOGY; ONCOLOGY; ORGANIZATION AND MANAGEMENT; PATHOLOGY; PROTO ONCOGENE; SPAIN; STOMACH TUMOR; UTILIZATION REVIEW;

ALGORITHMS; CARCINOMA; CLINICAL LABORATORY TECHNIQUES; CLINICAL TRIALS AS TOPIC; CONSENSUS; GENES, ERBB-2; GENETIC TESTING; HUMANS; MEDICAL ONCOLOGY; PATHOLOGY, MOLECULAR; PRACTICE GUIDELINES AS TOPIC; SOCIETIES, MEDICAL; SPAIN; STOMACH NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84855386274     PISSN: 1699048X     EISSN: 16993055     Source Type: Journal    
DOI: 10.1007/s12094-011-0709-7     Document Type: Article

References (41)

1. Bang YJ, Van Cutsem E, Feyereislova A et al (2010) Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastrooesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 376:687-697
2. Allison M (2010) The HER2 testing conundrum. Nat Biotechnol 28:117-119
3. Yamamoto T, Ikawa S, Akiyama T et al (1986) Similarity of protein encoded by the human cerb-B-2 gene to epidermal growth factor receptor. Nature 319:230-234 (Pubitemid 16128786)
4. Cortés-Funes H, Rivera F, Alés I et al (2007) Phase II of trastuzumab and cisplatin in patients (pts) with advanced gastric cancer (AGC) with HER2/neu overexpression/amplification. J Clin Oncol 2007 ASCO Annual Meeting Proceedings Part I. Vol 25, No. 18S (June 20 Supplement): 4613
5. Hofmann M, Stoss O, Shi D et al (2008) Assessment of a HER2 scoring system for gastric cancer: results from a validation study. Histopathology 52: 797-805 (Pubitemid 351724903)
6. Van Cutsem E, Kang Y, Chung H et al (2009) Efficacy results from the ToGA trial: a phase III study of trastuzumab added to standard chemotherapy (CT) in fi rst-line human epidermal growth factor receptor 2 (HER2)-positive advanced gastric cancer (GC). J Clin Oncol 27:18s (suppl; abstr LBA4509)
7. Bang Y, Chung H, Xu J et al (2009) Pathological features of advanced gastric cancer (GC): Relationship to human epidermal growth factor receptor 2 (HER2) positivity in the global screening programme of the ToGA trial. J Clin Oncol 27:15s (suppl; abstr 4556)
8. Ruschoff J, Dietel M, Baretton G et al (2010) HER2 diagnostics in gastric cancer-guideline validation and development of standardized immunohistochemical testing. Virchows Arch 457:299-307
9. García-García E, Gómez-Martín C, Angulo A et al. Hybridization for HER2 testing in gastric carcinoma: a comparison of fl uorescence in situ hybridization with a novel fully automated dualcolor silver in situ hybridization. Histopathology (in press)
10. Gómez Martín C (2010) Importancia pronóstica y predictiva del estudio del oncogen HER2 en adenocarcinomas gástricos. Doctoral thesis, Universidad Autónoma de Madrid
11. Zuo T, Wang L, Morrison C et al (2007) FOXP3 is an X-linked breast cancer suppressor gene and an important repressor of the HER-2/ErbB2 oncogene. Cell 129:1275-1286 (Pubitemid 46970708)
12. Cappuzzo F, Bemis L, Varella-Garcia M (2006) HER2 mutation and response to trastuzumab therapy in non-small-cell lung cancer. N Engl J Med 354:2619-2621 (Pubitemid 43882374)
13. Wang SE, Narasanna A, Perez-Torres M et al (2006) HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors. Cancer Cell 10:25-38
14. Sauter G, Simon R, Hillan K (2003) Tissue microarrays in drug discovery. Nat Rev Drug Discov 2:962-972 (Pubitemid 37540578)
15. Zhang XL, Yang YS, Xu DP et al (2009) Comparative study on overexpression of HER2/neu and HER3 in gastric cancer. World J Surg 33:2112-2118
16. Takehana T, Kunitomo K, Kono K et al (2002) Status of c-erbB-2 in gastric adenocarcinoma: a comparative study of immunohistochemistry, fl uorescence in situ hybridization and enzyme-linked immunosorbent assay. Int J Cancer 98:833-837 (Pubitemid 34286677)
17. Allgayer H, Babic R, Gruetzner KU et al (2000) c-erbB-2 is of independent prognostic relevance in gastric cancer and is associated with the expression of tumor-associated protease systems. J Clin Oncol 18:2201-2209 (Pubitemid 30350211)
18. Marx AH, Tharun L, Muth J et al (2009) HER-2 amplification is highly homogenous in gastric cancer. Hum Pathol 40:769-777
19. Yano T, Doi T, Ohtsu A et al (2006) Comparison of HER2 gene amplification assessed by fluorescence in situ hybridization and HER2 protein expression assessed by immunohistochemistry in gastric cancer. Oncol Rep 15:65-71
20. Lottner C, Schwarz S, Diermeier S et al (2005) Simultaneous detection of HER2/neu gene amplifi cation and protein overexpression in paraffi nembedded breast cancer. J Pathol 205:577-584 (Pubitemid 40514830)
21. Park DI, Yun JW, Park JH et al (2006) HER-2/neu amplifi cation is an independent prognostic factor in gastric cancer. Dig Dis Sci 51:1371-1379 (Pubitemid 44315804)
22. Nakajima M, Sawada H, Yamada Y et al (1999) The prognostic signifi cance of amplifi cation and overexpression of c-met and c-erb B-2 in human gastric carcinomas. Cancer 85:1894-1902 (Pubitemid 29202761)
23. Tanner M, Hollmén M, Junttila TT et al (2005) Amplification of HER-2 in gastric carcinoma: association with Topoisomerase IIalpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab. Ann Oncol 16:273-278 (Pubitemid 40309309)
24. Grabsch H, Sivakumar S, Gray S et al (2010) HER2 expression in gastric cancer: Rare, heterogeneous and of no prognostic value: conclusions from 924 cases of two independent series. Cell Oncol 32:57-65
25. Matsui Y, Inomata M, Tojigamori M et al (2005) Suppression of tumor growth in human gastric cancer with HER2 overexpression by an anti- HER2 antibody in a murine model. Int J Oncol 27:681-685
26. Rebischung C, Barnoud R, Stéfani L et al (2005) The effectiveness of trastuzumab (Herceptin) combined with chemotherapy for gastric carcinoma with overexpression of the c-erbB-2 protein. Gastric Cancer 8:249-252 (Pubitemid 41712637)
27. Inui T, Asakawa A, Morita Y et al (2006) HER-2 overexpression and targeted treatment by trastuzumab in a very old patient with gastric cancer. J Intern Med 260:484-487 (Pubitemid 44571137)
28. Rech J, Arnld D, Folprecht G et al (2006) A pilot study of Trastuzumab monotherapy in patients who progressed while on chemotherapy for metastatic or locally advanced HER positive gastric cancer. Ann Oncol 17[Suppl 9]:314 (abstract 1096P)
29. Nicholas G, Cripps C, Heather-Jane A et al (2006) Early results of a trial of trastuzumab, cisplatin and docetaxel (TCD) for the treatment of metastatic gastric cancer overexpressing HER2. Ann Oncol 17[Suppl 9]:316 (abstract 1105P)
30. Satoh T, Leon J, Lopez RI et al (2010) Quality of life results from a phase III trial of trastuzumab plus chemotherapy in first-line HER2-positive advanced gastric and GE junction cancer. 2010 Gastrointestinal Cancers Symposium, Abstract 7
31. Wainberg ZA, Anghel A, Desai AJ et al (2010) Lapatinib, a dual EGFR and HER2 kinase inhibitor, selectively inhibits HER2-amplifi ed human gastric cancer cells and is synergistic with trastuzumab in vitro and in vivo. Clin Cancer Res 16:1509-1519
32. Wolff AC, Hammond ME, Schwartz JN et al; American Society of Clinical Oncology; College of American Pathologists (2007) American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 25:118-145 (Pubitemid 350003059)
33. Risio M, De Rosa G, Sarotto L et al (2003) HER2 testing in gastric cancer: molecular morphology and storage time-related changes in archival samples. Int J Oncol 23:1381-1387
34. Werner M, Chott A, Fabiano A, Battifora H (2000) Effect of formalin tissue fixation and processing on immunohistochemistry. Am J Surg Pathol 24:1016-1019 (Pubitemid 30430490)
35. Goldstein NS, Hewitt SM, Taylor CR et al; members of Ad-Hoc Committee on Immunohistochemistry Standardization (2007) Recommendations for improved standardization of immunohistochemistry. Appl Immunohistochem Mol Morphol 15:124-133 (Pubitemid 46828218)
36. Burnett MG (1982) The mechanism of the formaldehyde clock reaction. J Chem Educ 59:160-162
37. Grace-Jones W (2008) Tissue microarray. In: Bancroft JD, Gamble M (eds) Theory and practice of histological techniques, 6th edn. Churchill Livingstone, Elsevier, Philadelphia, pp 527-535
38. Blind C, Koepenik A, Pacyna-Gengelbach M et al (2008) Antigenicity testing by immunohistochemistry after tissue oxidation. J Clin Pathol 61:79-83 (Pubitemid 351158230)
39. Hatanaka Y, Hashizume K, Kamihara Y et al (2001) Quantitative immunohistochemical evaluation of HER2/neu expression with HerceptestTM in breast carcinoma by image analysis. Pathol Int 51:33-36 (Pubitemid 32158809)
40. Mulrane L, Rexhepaj E, Penney S et al (2008) Automated image analysis in histopathology: a valuable tool in medical diagnostics. Exp Rev Mol Diagn 8:707-725
41. Persons DL, Tubbs RR, Cooley LD et al (2006) HER-2 fluorescence in situ hybridization. Results from the Survey Program of the College of American Pathologists. Arch Pathol Lab Med 130:325-331